je.st
news
Tag: small
Inland Mortgage Capital President Discusses the Rules for Playing in the Small Bridge Loan Space
2017-06-16 13:00:00| National Real Estate Investor
In a Q&A with NREI, Art Rendak, president of Inland Mortgage Capital, discusses what the future holds for short-term bridge loans ranging from $3 million to $12 million.
Tags: small
capital
rules
space
Small Town To Capital City: Rural Michigans Political Couple
2017-04-26 14:34:11| Country Lines Online
Down a country road in Ionia County, not too far from where she grew up on a sesquicentennial farm, Julie Calley lives a fairly normal life. Julie is a wife, mother of three and devoted public servant. Of course, shes also married to the lieutenant governor of Michigan, Brian Calley, but her career takes her […]
Canon Maxify iB4120 Wireless Small Office Inkjet Printer
2017-02-08 11:05:15| PC Magazine Ink Jet Printers Product Guide
The Canon Maxify iB4120 Wireless Small Office Inkjet Printer is inexpensive, but provides generous paper capacity, competitive running costs, solid speed, and excellent output quality.
Tags: office
small
printer
wireless
Oracle Procurement Cloud Blog Part III: Why build a skyscraper if your need is a small apartment building?
2017-01-30 15:28:56| Capgemini News Feed
Language Worldwide Jeroen Sprangers Share: Share this page Search Keyword: oracle, procurement cloud, procurement, cloud, business transformation
Updated KEYTRUDA (pembrolizumab) Data in Small Cell Lung Cancer and Mesothelioma Presented at 17th World Conference on Lung Cancer
2016-12-06 14:20:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Findings in Small Cell Lung Cancer and Malignant Pleural Mesothelioma Show Overall Response Rates of 33.3 Percent and 20.0 Percent, Respectively, in KEYNOTE-028 Long-Term Data Demonstrate Durable Responses in Difficult-to-Treat Cancers KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that updated findings from the phase 1b KEYNOTE-028 study investigating the use of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in previously treated patients with advanced small cell lung cancer (SCLC) and malignant pleural mesothelioma, showed clinical activity and durable responses in some patients. Language: English Contact: Media:Pamela Eisele, 267-305-3558orCourtney Ronaldo, 908-236-1108orInvestorsTeri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more
Sites : [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] next »